ArticleNature communications2022
Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 90 citations in OpenAlex.
- Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.Cancer biology & therapy · 2026Review
- Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity.bioRxiv : the preprint server for biology · 2026Article
- Immunopeptidomics reveals conserved and abundant Francisella tularensis proteins as immunogenic CD4 T cell antigens in mice.PLoS pathogens · 2026Article
- The Ratio of Immunogenicity: A quantitative metric to identify highly immunogenic protein antigens to improve tissue-engineered biomaterials.Biomaterials · 2026Article
- An mRNA-Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-ResistantbioRxiv : the preprint server for biology · 2026Article
- Immunotherapeutic modalities for combating multidrug-resistant bacteria: therapeutic promises of antibodies and next-generation vaccines.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A Platform for High-throughput and Ultrasensitive Immunopeptidomics.Molecular & cellular proteomics : MCP · 2026Article
- Identification of a persistent Ascaris-derived Kalirin epitope associated with chronic T cell activation in the lung.PLoS neglected tropical diseases · 2026Article
- AddaVax-Adjuvanted Inactivated Vaccine Confers Protection Against Listeria monocytogenes Challenge in Mice.Current microbiology · 2026Article
- Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens.Biomaterials research · 2026Review
- Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape.Frontiers in immunology · 2026Article
- Article
- Data-Independent Immunopeptidomics Discovery of Low-Abundant Bacterial Epitopes.Journal of proteome research · 2025Article
- Mimicry in the Bite: Shared Sequences BetweenProteomes · 2025Article
- Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery.The Journal of experimental medicine · 2025Article
- A multivalent mRNA-LNP cocktail vaccine confers superior efficacy against Staphylococcus aureus infection in murine models.NPJ vaccines · 2025Article
- Global burden ofTranslational pediatrics · 2025Article
- HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry.Journal for immunotherapy of cancer · 2025Article
- Challenges and opportunities in mRNA vaccine development against bacteria.Nature microbiology · 2025Review
- Intranasal delivery of mRNA expressing newly identified Acinetobacter baumannii antigens protects against bacterial lung disease.NPJ vaccines · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Listeria monocytogenes is a foodborne intracellular bacterial pathogen leading to human listeriosis. Despite a high mortality rate and increasing antibiotic resistance no clinically approved vaccine against Listeria is available. Attenuated Listeria strains offer protection and are tested as antitumor vaccine vectors, but would benefit from a better knowledge on immunodominant vector antigens. To identify novel antigens, we screen for Listeria peptides presented on the surface of infected human cell lines by mass spectrometry-based immunopeptidomics. In between more than 15,000 human self-peptides, we detect 68 Listeria immunopeptides from 42 different bacterial proteins, including several known antigens. Peptides presented on different cell lines are often derived from the same bacterial surface proteins, classifying these antigens as potential vaccine candidates. Encoding these highly presented antigens in lipid nanoparticle mRNA vaccine formulations results in specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.